开角型青光眼

Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. 摘要

International Council of Ophthalmology. ICO guidelines for glaucoma eye care. Feb 2016 [internet publication].全文

American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. Nov 2020 [internet publication].全文

American Academy of Ophthalmology. Primary open-angle glaucoma suspect preferred practice pattern. Nov 2020 [internet publication].全文

National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. Jan 2022 [internet publication].全文

1. Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. 摘要

2. World Health Organization. World report on vision. Oct 2019 [internet publication].全文

3. International Council of Ophthalmology. ICO guidelines for glaucoma eye care. Feb 2016 [internet publication].全文

4. US National Eye Institute. Types of glaucoma. Sep 2021 [internet publication].全文

5. American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. Nov 2020 [internet publication].全文

6. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):532-8.全文  摘要

7. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991 Nov 14;325(20):1412-7.全文  摘要

8. Varma R, Ying-Lai M, Francis BA, et al; Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004 Aug;111(8):1439-48. 摘要

9. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991 Jul 17;266(3):369-74. 摘要

10. American Academy of Ophthalmology. Primary open-angle glaucoma suspect preferred practice pattern. Nov 2020 [internet publication].全文

11. Fingert JH, Stone EM, Sheffield VC, et al. Myocilin glaucoma. Surv Ophthalmol. 2002 Nov-Dec;47(6):547-61. 摘要

12. Fingert JH. Primary open-angle glaucoma genes. Eye (Lond). 2011 May;25(5):587-95.全文  摘要

13. Fahy ET, Chrysostomou V, Crowston JG. Mini-review: impaired axonal transport and glaucoma. Curr Eye Res. 2016;41(3):273-83. 摘要

14. Delaney Y, Walshe TE, O'Brien C. Vasospasm in glaucoma: clinical and laboratory aspects. Optom Vis Sci. 2006 Jul;83(7):406-14. 摘要

15. Khaw PT, Shah P, Elkington AR. Glaucoma-1: diagnosis. BMJ. 2004 Jan 10;328(7431):97-9.全文  摘要

16. Kreft D, Doblhammer G, Guthoff RF, et al. Prevalence, incidence, and risk factors of primary open-angle glaucoma - a cohort study based on longitudinal data from a German public health insurance. BMC Public Health. 2019 Jul 1;19(1):851.全文  摘要

17. Xu L, Wang Y, Wang S, et al. High myopia and glaucoma susceptibility. The Beijing Eye Study. Ophthalmology. 2007 Feb;114(2):216-20. 摘要

18. Zhou M, Wang W, Huang W, et al. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2014;9(8):e102972.全文  摘要

19. Zhao D, Cho J, Kim MH, et al. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015 Jan;122(1):72-8.全文  摘要

20. Zhao YX, Chen XW. Diabetes and risk of glaucoma: systematic review and a meta-analysis of prospective cohort studies. Int J Ophthalmol. 2017;10(9):1430-5.全文  摘要

21. Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006 Jul;113(7):1069-76. 摘要

22. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995 Feb;113(2):216-21. 摘要

23. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008 Jan;115(1):85-93. 摘要

24. Leske MC, Heijl A, Hyman L, et al; EMGT Group. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007 Nov;114(11):1965-72. 摘要

25. Francis BA, Varma R, Chopra V, et al; Los Angeles Latino Eye Study Group. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008 Nov;146(5):741-6.全文  摘要

26. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. Jan 2022 [internet publication].全文

27. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20. 摘要

28. Hollands H, Johnson D, Hollands S, et al. Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. JAMA. 2013 May 15;309(19):2035-42. 摘要

29. Dueker DK, Singh K, Lin SC, et al. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2007 Sep;114(9):1779-87. 摘要

30. Healey PR, Mitchell P. Presence of an optic disc notch and glaucoma. J Glaucoma. 2015 Apr-May;24(4):262-6. 摘要

31. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996 Oct;103(10):1661-9. 摘要

32. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004 May 22;363(9422):1711-20. 摘要

33. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64. 摘要

34. Quigley HA, Katz J, Derick RJ, et al. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology. 1992 Jan;99(1):19-28.全文  摘要

35. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences - The Rotterdam Study. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3309-21.全文  摘要

36. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007 Oct;11(41):iii-iv, ix-x, 1-190.全文  摘要

37. Soh Z, Yu M, Betzler BK, et al. The global extent of undetected glaucoma in adults: a systematic review and meta-analysis. Ophthalmology. 2021 Oct;128(10):1393-404.全文  摘要

38. Chou R, Selph S, Blazina I, et al. Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 May 24;327(20):1998-2012.全文  摘要

39. US Preventive Services Task Force (USPSTF). Final recommendation statement. Primary open-angle glaucoma: screening. May 2022 [internet publication].全文

40. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005 Jul 16;331(7509):134.全文  摘要

41. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011 Sep;118(9):1766-73. 摘要

42. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018 May;96(3):e277-84.全文  摘要

43. Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585-93. 摘要

44. Tang W, Zhang F, Liu K, et al. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine (Baltimore). 2019 Jul;98(30):e16597.全文  摘要

45. Weinreb RN, van Buskirk EM, Cherniack R, et al. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol. 1988 Aug 15;106(2):162-7. 摘要

46. Coleman AL, Robin AL, Pollack IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol. 1990;108:1264-1267. 摘要

47. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006 Sep;124(9):1230-8. 摘要

48. Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye (Lond). 2010;24:1234-1242. 摘要

49. Diestelhorst M, Larsson LI; European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006 Jan;113(1):70-6. 摘要

50. Waterman H, Evans JR, Gray TA, et al. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006132.全文  摘要

51. Oddone F, Tanga L, Kóthy P, et al; VISIONARY Study Group. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther. 2020 Apr;37(4):1436-51.全文  摘要

52. Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, et al. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD003919.全文  摘要

53. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019 Apr 13;393(10180):1505-16.全文  摘要

54. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess. 2019 Jun;23(31):1-102.全文  摘要

55. Wright DM, Konstantakopoulou E, Montesano G, et al; Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) Study Group. Visual field outcomes from the multicenter, randomized controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). Ophthalmology. 2020 Oct;127(10):1313-21. 摘要

56. Wong MO, Lee JW, Choy BN, et al. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015 Jan-Feb;60(1):36-50. 摘要

57. Brown SV, Thomas JV, Simmons RJ. Laser trabeculoplasty re-treatment. Am J Ophthalmol. 1985 Jan 15;99(1):8-10. 摘要

58. Starita RJ, Fellman RL, Spaeth GL, et al. The effect of repeating full-circumference argon laser trabeculoplasty. Ophthalmic Surg. 1984 Jan;15(1):41-3. 摘要

59. Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev. 2017 Feb 23;(2):CD010746.全文  摘要

60. Zhang ML, Hirunyachote P, Jampel H. Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma. Cochrane Database Syst Rev. 2015 Jul 14;(7):CD008671.全文  摘要

61. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013 Dec;131(12):1573-82.全文  摘要

62. Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018 Jan;27(1):7-15. 摘要

63. Canadian Agency for Drugs and Technologies in Health. Clinical review report: latanoprostene bunod (Vyzulta) (Bausch Health, Canada Inc.). Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2019.全文  摘要

64. Serle JB, Katz LJ, McLaurin E, et al; ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-27.全文  摘要

65. Asrani S, Robin AL, Serle JB, et al; MERCURY-1 Study Group. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019 Nov;207:248-57.全文  摘要

66. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020 Sep-Oct;3(5):327-38.全文  摘要

67. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2017 Jan 25;(1):CD006539.全文  摘要

68. King AJ, Shah A, Nikita E, et al. Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma. Cochrane Database Syst Rev. 2018 Dec 16;(12):CD012742.全文  摘要

69. Otarola F, Virgili G, Shah A, et al. Ab interno trabecular bypass surgery with Schlemm's canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst Rev. 2020 Mar 9;3(3):CD012740.全文  摘要

70. Wang X, Khan R, Coleman A. device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010472.全文  摘要

71. Hu K, Shah A, Virgili G, et al. Ab interno trabecular bypass surgery with Trabectome for open-angle glaucoma. Cochrane Database Syst Rev. 2021 Feb 4;(2):CD011693.全文  摘要

72. Augustinus CJ, Zeyen T. The effect of phacoemulsification and combined phaco/glaucoma procedures on the intraocular pressure in open-angle glaucoma. A review of the literature. Bull Soc Belge Ophtalmol. 2012;(320):51-66.全文  摘要

73. Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016 Apr 26;10:757-64.全文  摘要

74. Brandt JD, DuBiner HB, Benza R, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017 Oct;124(10):1565-6.全文  摘要

75. Gote V, Sikder S, Sicotte J, et al. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019 Sep;370(3):602-24.全文  摘要

76. Wong TT, Novack GD, Natarajan JV, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2014 Aug;4(4):303-9. 摘要

77. Gutiérrez-Hernández JC, Caffey S, Abdallah W, et al. One-year feasibility study of Replenish MicroPump for intravitreal drug delivery: a pilot study. Transl Vis Sci Technol. 2014 July;3(4):1.全文  摘要

78. Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020 Feb;80(2):167-79.全文  摘要

79. Dick HB, Schultz T, Gerste RD. Miniaturization in glaucoma monitoring and treatment: a review of new technologies that require a minimal surgical approach. Ophthalmol Ther. 2019 Mar;8(1):19-30.全文  摘要

80. National Institute for Health and Care Excellence. Clinical knowledge summaries. Glaucoma: what is the prognosis? Feb 2023 [internet publication].全文

81. Malihi M, Moura Filho ER, Hodge DO, et al. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014 Jan;121(1):134-41.全文  摘要

82. Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013 Oct;156(4):724-30.全文  摘要